The comparative effectiveness of anti-craving agents in alcohol depence syndrome

The comparative effectiveness of acamprosate, naltrexone, and baclofen in alcohol dependence syndrome A randomized open-label trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069763

Enrollment

Registered

2024-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

Control Intervention1: Naltrexone: 50mg orally to be added in baseline and patient to be followed-up after 1 and 3 months Control Intervention2: Acamprosate: 1332mg(if body weight less than 60kg) and

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with ADS as per ICD-10 and who have completed the withdrawal management, ASSIST score cut-off is less than high-risk except for tobacco, written informed consent.

Exclusion criteria

Exclusion criteria: Any psychiatric or physical diagnosis which can interfere with informed consent, participation in the study.

Design outcomes

Primary

Measure	Time frame
The number of days abstinent from alcoholTimepoint: baseline, 1month and 3months	—

Secondary

Measure	Time frame
The number of heavy drinking days as per Time Line Follow Back, Craving, Number of dropoutsTimepoint: 1 month and 3 months	—

Countries

India

Contacts

Public ContactDrAindrila Dutta

Lokopriya Gopinath Bordoloi regional institute of mental health

dr.soumiksengupta@gmail.com8471937677

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026